On this page
Quick Reference
Overview and Recommendations
Background
- •Non-small cell lung cancer (NSCLC) accounts for ~85% of all lung cancers, and radiation therapy plays a central role across all stages, from definitive stereotactic ablative radiotherapy (SABR) for early-stage disease to concurrent chemoradiation for unresectable stage III and palliative RT for symptom control in advanced disease. The 5-year survival for stage III NSCLC remains under 30%, driving the need to optimize both tumor control and patient quality of life.
- •Definitive chemoradiation, combining platinum-based chemotherapy with thoracic radiotherapy, is the standard of care for unresectable stage II-III NSCLC, following landmark trials that demonstrated a survival benefit over RT alone. The concurrent approach offers a radiosensitizing effect and addresses micrometastases, but at the cost of increased acute esophagitis and pneumonitis.
- •Dose escalation beyond 60-66 Gy has been explored to improve local control, with the ARTFORCE PET-Boost trial evaluating an individualized regimen of 24 × 3.0-5.4 Gy to the primary tumor in patients with a tumor ≥4 cm. This strategy delivers a biologically equivalent dose >80 Gy while respecting organ-at-risk constraints, and the trial showed that average health-related quality of life (HRQoL) remained stable over 12 months, despite some transient symptom burdens.
- •The paradigm of radiation management for NSCLC increasingly emphasizes patient-reported outcomes (PROs) alongside traditional endpoints. The ARTFORCE trial set a new standard by reporting PROs using EORTC QLQ-C30 and QLQ-LC13, revealing that clinically meaningful worsening of dyspnoea occurs at 3-6 months and physical functioning declines gradually, even when global HRQoL is preserved. This dissociation between symptoms and global QoL has important implications for counseling and proactive management.
- •Radiation techniques have evolved from conventional 2D planning to modern intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT), allowing steep dose gradients and sparing of organs at risk such as the lung (mean lung dose <20 Gy, V20 <35%), heart (mean <26 Gy), spinal cord (max <50 Gy), and esophagus. These advances make dose escalation feasible without prohibitive toxicity, though careful patient selection remains critical.
Evaluation
- •Suspect the need for definitive radiation therapy in any patient with stage II-III NSCLC who is not a surgical candidate due to medical comorbidities, tumor extent, or patient preference. Also consider RT in the adjuvant setting for positive margins or nodal involvement after surgery, and for palliation of symptoms such as hemoptysis, pain, or airway obstruction.
- •Ask about the patient's performance status (ECOG 0-1 generally required for concurrent chemoradiation), smoking history, pulmonary function (baseline dyspnea, COPD), and any prior thoracic radiation that would limit dose.
- •Examine the patient for signs of superior vena cava syndrome, stridor, or distant metastases. Assess weight loss and nutritional status, as cachexia may affect tolerance to treatment.
- •Order a staging PET/CT to define the extent of disease and identify the most FDG-avid subvolume of the primary tumor, which may be used for dose-escalation planning. Obtain a diagnostic contrast-enhanced CT of the chest and upper abdomen, and brain MRI to rule out intracranial metastases.
- •Perform pulmonary function tests (PFTs) including FEV1 and DLCO to assess baseline lung reserve; a low FEV1 (<40% predicted) or DLCO may increase the risk of radiation pneumonitis and influence the decision for concurrent chemotherapy.
- •Assess eligibility for dose escalation: the ARTFORCE trial offered dose-escalated RT (24 × 3.0-5.4 Gy) to patients with a primary tumor ≥4 cm. Consider this strategy in patients with adequate lung function and tumor geometry that allows meeting OAR constraints.
- •Discuss the benefit-toxicity trade-off with the patient: explain that dose escalation may improve local control but is associated with transient worsening of dyspnea at 3-6 months and a gradual decline in physical function that can persist at 18 months. Emphasize that average global HRQoL is likely to remain stable.
- •Plan simulation with the patient in a reproducible position (supine, arms up), using a 4D CT scan to account for respiratory motion. Consider gating or breath-hold techniques if tumor motion exceeds 1 cm.
- •Define target volumes: GTV includes the primary tumor and involved nodes; CTV adds a 0.5-1 cm margin; PTV adds an additional margin for setup uncertainty. For dose escalation, the high-dose volume may be the whole tumor or the FDG-avid subvolume.
- •Apply OAR constraints: spinal cord max <50 Gy, lung mean <20 Gy and V20 <35%, heart mean <26 Gy and V30 <46%, esophagus mean <34 Gy and V35 <50%. These constraints are critical to minimize late toxicity.
- •Monitor for acute toxicity during treatment: weekly assessment of dysphagia, fatigue, and weight loss. Consider prophylactic nutritional support (e.g., enteral feeding if weight loss >5%) and use of oral mucositis protocols.
- •After treatment, follow up with clinical evaluation and imaging at 3, 6, 12, and 18 months. Assess for late dyspnea (suggestive of radiation pneumonitis) and declining physical function. Use PRO questionnaires (e.g., EORTC QLQ-C30) to capture symptom burden systematically.
Management
- •For stage III unresectable NSCLC with good performance status (ECOG 0-1), initiate definitive concurrent chemoradiation: deliver 60-66 Gy in 30-33 fractions (1.8-2.0 Gy/fraction) with cisplatin 50 mg/m² on days 1, 8, 29, 36 and etoposide 50 mg/m² on days 1-5, 29-33. Alternatively, use carboplatin AUC 5 day 1 + paclitaxel 50 mg/m² weekly during RT.
- •For patients with a primary tumor ≥4 cm who are candidates for dose escalation, consider the ARTFORCE regimen: 24 fractions of 3.0-5.4 Gy (individualized to OAR constraints) to the whole tumor or the FDG-avid subvolume. This can be delivered with concurrent or sequential chemotherapy, or RT alone. Monitor PROs closely.
- •For patients with ECOG 2 or contraindications to concurrent chemotherapy, administer sequential chemoradiation: 2-4 cycles of platinum-doublet chemotherapy followed by RT (60-66 Gy/30-33 fx). Alternatively, RT alone can be used for frail patients.
- •For early-stage (stage I) NSCLC, use stereotactic ablative radiotherapy (SABR): 48-60 Gy in 3-5 fractions (e.g., 54 Gy/3 fx for peripheral tumors, 50 Gy/5 fx for central tumors). This is not discussed in the provided evidence but is a standard first-line RT option for medically inoperable patients.
- •For postoperative adjuvant RT, consider RT (50-60 Gy in 25-30 fx) for patients with positive margins or N2 nodal involvement. The decision should be multidisciplinary, balancing the risk of local recurrence against increased toxicity.
- •For palliation of symptoms (e.g., hemoptysis, pain, dyspnea from airway obstruction), deliver hypofractionated RT: 30 Gy in 10 fractions, 20 Gy in 5 fractions, or 8-10 Gy single fraction for bone metastases. Use IMRT/VMAT to spare surrounding normal tissues.
- •Integrate chemotherapy with RT: for concurrent chemoradiation, use cisplatin-based regimens as first-line. For patients with impaired renal function or hearing loss, substitute carboplatin. Avoid concurrent use of targeted therapies or immune checkpoint inhibitors with RT unless part of a clinical trial.
- •Titrate supportive care: start prophylactic dexamethasone 0.5 mg/kg/day IV (or equivalent) for esophagitis pain, and consider proton pump inhibitors. Use enteral feeding if oral intake is inadequate. Manage radiation pneumonitis with prednisone 1 mg/kg/day tapered over 4-6 weeks.
- •Monitor for acute toxicity during treatment: weekly CBC, weight, and toxicity assessment. For grade ≥3 esophagitis (NCI CTCAE), hold chemotherapy and consider RT breaks. For grade ≥3 pneumonitis, start corticosteroids and hold RT.
- •After treatment, schedule follow-up visits at 3, 6, 12, and 18 months, then annually. Perform CT chest at each visit. Assess for late effects: radiation fibrosis, pericarditis, myelopathy. Use PRO tools to capture dyspnea and physical functioning.
- •What NOT to do: do not escalate dose without respecting OAR constraints; do not use concurrent chemo in patients with ECOG ≥2 or severe PFT impairment; do not ignore PROs, proactively address dyspnea and fatigue with pulmonary rehabilitation and exercise programs.
- •Refer to a radiation oncologist for all patients with NSCLC who may benefit from RT. Refer to a medical oncologist for systemic therapy integration. Refer to a palliative care specialist for symptom management and advanced care planning, especially in the metastatic setting.
- •Discharge criteria: after completing RT, patients can be discharged from the radiation oncology clinic when acute toxicity is resolved (typically 2-4 weeks after last fraction) and follow-up imaging is scheduled. Provide survivorship care plan including monitoring for late effects.
Board Review — High Yield
- •Concurrent chemoradiation, Standard of care for stage III unresectable NSCLC; improves OS over RT alone. Use cisplatin/etoposide or carboplatin/paclitaxel.
- •Standard dose, 60-66 Gy in 30-33 fractions (1.8-2.0 Gy/fx). Deliver with IMRT/VMAT to spare OARs.
- •Dose escalation, ARTFORCE trial: 24 × 3.0-5.4 Gy for primary tumor ≥4 cm; preserves average HRQoL but causes transient dyspnea at 3-6 months.
- •OAR constraints, Lung: V20 <35%, mean <20 Gy; Heart: mean <26 Gy, V30 <46%; Spinal cord: max <50 Gy; Esophagus: mean <34 Gy, V35 <50%.
- •Patient-reported outcomes, EORTC QLQ-C30 and LC13; compliance drops during RT (35%) but recovers. Global QoL stable despite symptom burden.
- •Palliative RT, Hypofractionated regimens: 30 Gy/10 fx, 20 Gy/5 fx, or 8-10 Gy single for bone metastases. Effective for hemoptysis, pain, obstruction.
- •Adjuvant RT, Consider for positive margins or N2 disease post-surgery; dose 50-60 Gy in 25-30 fx. Balance benefit with increased cardiac/pulmonary toxicity.
- •Toxicity monitoring, Acute: esophagitis, fatigue, weight loss. Late: pneumonitis (dyspnea at 3-6 months), radiation fibrosis, pericarditis. Proactive symptom management is key.
Deep Dive — Evidence Details
Indications by Stage
- ▸Definitive chemoradiation is indicated for stage II-III NSCLC with primary tumor ≥4 cm, supported by ARTFORCE PET-Boost trial PRO data.
- ▸Dose-escalation to 24 × 3.0-5.4 Gy does not significantly alter average HRQoL, though dyspnoea and physical function decline transiently.
- ▸Adjuvant and palliative RT indications are standard but not addressed by the provided evidence.
Radiation therapy for (NSCLC) is indicated across a spectrum of disease stages, with the strongest evidence supporting definitive chemoradiation for locally advanced (stage II-III) disease. The ARTFORCE PET-Boost trial provides contemporary patient-reported outcome data for this setting, evaluating dose-escalation strategies in patients with a primary tumor ≥4 cm [1]B2b.
Definitive Chemoradiation for Stage II-III NSCLC
For patients with stage II-III NSCLC who are not surgical candidates, definitive radiotherapy, often combined with chemotherapy, is the standard of care. The ARTFORCE trial enrolled patients receiving sequential or concurrent chemoradiotherapy or radiotherapy alone, randomizing them to an individualized escalated fraction dose of 24 fractions × 3.0-5.4 Gy to either the whole primary tumor or its most FDG-avid subvolume [1]B2b.
- Patient-reported outcomes (PROs) were assessed using EORTC QLQ-C30, QLQ-LC13, and EuroQol-5D at eight timepoints. Compliance was highest at baseline (86.3%) and lowest during radiation treatment (35.0%) [1]B2b.
- Health-related quality of life (HRQoL) remained stable over time, with no significant difference between the two dose-escalation groups [1]B2b.
- Symptoms: Clinically meaningful worsening of dyspnoea occurred mainly at 3 and 6 months; physical functioning showed a gradual decline during treatment and at 18 months [1]B2b.
These findings indicate that dose-escalated radiotherapy can be delivered without a sustained negative impact on average HRQoL, despite transient symptom burdens. The choice of dose-escalation strategy (whole-tumor vs. subvolume boost) did not differentially affect PROs.
Adjuvant and Palliative Indications
While the ARTFORCE trial focused on definitive treatment, radiation therapy is also indicated in the adjuvant setting (postoperative for positive margins or nodal involvement) and for palliation of symptoms such as pain, hemoptysis, or airway obstruction. Evidence for these indications derives from other trials and is discussed in subsequent sections of this article.
Pearl: In locally advanced NSCLC with a primary tumor ≥4 cm, dose-escalated radiotherapy (24 × 3.0-5.4 Gy) maintains average patient-reported quality of life, but clinicians should monitor for dyspnoea at 3-6 months and declining physical function during and after treatment [1]B2b.
| Stage | Tumor Size | Treatment Setting | Dose Regimen | Key PRO Finding |
|---|---|---|---|---|
| II-III | ≥4 cm | Definitive (with or without chemo) | 24 × 3.0-5.4 Gy (individualized escalation) | Stable HRQoL; dyspnoea worsens at 3-6 months [1]B2b |
External Beam Radiotherapy (EBRT)
- ▸Standard fractionation for locally advanced NSCLC is 60-66 Gy in 30-33 fractions; dose-escalation to 24 × 3.0-5.4 Gy was tested in the ARTFORCE trial.
- ▸In ARTFORCE, overall HRQoL remained stable despite dose-escalation, but clinically meaningful worsening of dyspnoea occurred at 3 and 6 months, and physical functioning declined through 18 months.
- ▸Patient-reported outcomes should be integrated into the evaluation of dose-escalation strategies to capture the benefit-toxicity trade-off beyond survival endpoints.
Once a patient is selected for definitive radiotherapy based on stage, the radiation oncologist must choose the external beam technique, dose, and fractionation that maximize the therapeutic ratio. The evidence from the ARTFORCE PET-Boost trial provides a concrete example of dose-escalation and its associated patient-reported outcomes (PROs), which directly inform the clinical decision-making process.
Dose Fractionation Strategies
Standard fractionation for locally advanced (NSCLC) delivers 60-66 Gy in 30-33 fractions (≈ 1.8-2.0 Gy per fraction), a regimen that balances local control with acceptable toxicity. However, the desire to improve local failure rates has driven investigation of dose-escalation. The international, randomised, phase 2 ARTFORCE PET-Boost study (NCT01024829) enrolled patients with stage II-III NSCLC and a primary tumour ≥ 4 cm. The experimental arm received an individualised, escalated fraction dose of 24 × 3.0-5.4 Gy, delivered either to the whole primary tumour or to its most FDG-avid subvolume [1]B2b. This high-dose-per-fraction regimen (biologically equivalent to a conventional dose > 80 Gy) was designed to escalate the tumour dose while respecting organ-at-risk (OAR) constraints. The trial allowed sequential or concurrent chemoradiotherapy, or radiotherapy alone, reflecting real-world practice.
Patient-Reported Outcomes and the Benefit-Toxicity Trade-off
The ARTFORCE trial prospectively collected PROs using EORTC QLQ-C30, QLQ-LC13, and EuroQol-5D at eight timepoints. Compliance was high at baseline (86.3 %), 3 months (85.3 %), and 12 months (80.3 %), with the lowest rate during radiation treatment (35.0 %) [1]B2b. A linear mixed-effect model showed no significant change in overall health-related quality of life (HRQoL) over time and no significant difference between the two dose-escalation groups [1]B2b. Despite this, clinically meaningful worsening of dyspnoea was seen mainly at 3 and 6 months, and physical functioning showed a gradual decline in both groups during treatment and at 18 months follow-up [1]B2b. These findings illustrate that dose-escalation can be delivered without a net detriment to global HRQoL, but that pulmonary symptoms and physical deconditioning are common and warrant proactive monitoring. The trade-off between improved local control and increased symptomatic toxicity must be discussed with each patient.
Technique and Planning
Modern for NSCLC relies on intensity-modulated radiotherapy ( ) or ( ) to achieve conformal dose distribution. The ARTFORCE trial used individualised dose painting, either to the entire tumour or to the FDG-avid subvolume defined by PET CT, highlighting the role of functional imaging in target definition [1]B2b. Gating or breath-hold techniques may be used to manage respiratory motion, though this was not reported in the provided evidence. Achieving steep dose gradients around the target is critical to deliver the escalated fraction doses while respecting OAR constraints.
Organ at Risk Constraints
The provided evidence does not specify the OAR constraints used in the ARTFORCE trial. Standard clinical practice routinely limits dose to the spinal cord (max < 50 Gy), lung (mean lung dose < 20 Gy, V20 < 35 %), heart (mean < 26 Gy, V30 < 46 %), and esophagus (mean < 34 Gy, V35 < 50 %). These constraints are essential to minimise the risk of pneumonitis, esophagitis, pericarditis, and myelopathy. The absence of reported OAR data in this evidence underscores the need for all dose-escalation protocols to report both tumour dose and OAR doses to enable meaningful comparison of toxicity.
Integration with Systemic Therapy
Dose-escalation in the ARTFORCE trial was delivered with sequential or concurrent chemoradiotherapy or radiotherapy alone [1]B2b. The interaction between dose and systemic therapy is covered in the concurrent chemoradiation section. The EBRT technique must account for the additional radiosensitisation from platinum-based chemotherapy, which can increase esophagitis and pneumonitis. In the trial, despite dose-escalation, overall HRQoL remained stable, suggesting that the integration of chemotherapy with escalated RT is feasible but requires careful attention to supportive care.
Pearl: When considering dose-escalation for locally advanced NSCLC, the ARTFORCE trial demonstrates that overall HRQoL may be preserved, but patients should be counselled about the risk of transient dyspnoea at 3-6 months and a decline in physical functioning that persists at 18 months; proactive pulmonary rehabilitation and symptom management are warranted.
Brachytherapy
- ▸The ARTFORCE trial did not evaluate brachytherapy; its findings are limited to EBRT dose-escalation.
- ▸Patient-reported HRQoL remained stable after dose-escalated EBRT despite transient worsening of dyspnoea, dysphagia, and fatigue.
- ▸Brachytherapy's role in NSCLC is not supported by the provided evidence; clinicians should rely on EBRT-based data for guidance.
Building on the ( ) foundation, is not a standard component of definitive NSCLC management based on the available evidence. The ARTFORCE trial [1]B2b evaluated dose-escalation strategies using EBRT alone and did not include brachytherapy, leaving its role in NSCLC unaddressed by the provided literature. The trial's findings on patient-reported outcomes (PROs) after dose-escalated EBRT, however, offer insights relevant to any radiation therapy approach where dose escalation is considered.
Patient-Reported Outcomes After Dose-Escalated Radiotherapy
The ARTFORCE PET-Boost study (NCT01024829) randomised 107 patients with stage II-III NSCLC and a primary tumour ≥4 cm to receive an individualised escalated fraction dose (24 fractions of 3.0-5.4 Gy) to either the whole primary tumour or its most FDG-avid subvolume [1]B2b. Patients received sequential or concurrent chemoradiotherapy, or radiotherapy alone. The study assessed health-related quality of life (HRQoL) using EORTC QLQ-C30, QLQ-LC13, and EuroQol-5D at eight time points.
Key PRO findings from the ARTFORCE trial [1]B2b:
- Compliance rates: baseline 86.3%, 3 months 85.3%, 12 months 80.3%; lowest during radiation treatment (35.0%).
- A linear mixed-effect model showed no significant change in overall HRQoL over time and no significant difference between the two dose-escalation groups.
- Physical functioning showed a gradual decline in both groups during treatment and at 18 months follow-up.
- Clinically meaningful worsening of dyspnoea was seen mainly at 3 and 6 months.
- Frequent patient-reported symptoms included dyspnoea, dysphagia, and fatigue.
| Timepoint | Compliance Rate |
|---|---|
| Baseline | 86.3% |
| 3 months | 85.3% |
| 12 months | 80.3% |
| During RT | 35.0% |
Implications for Brachytherapy
Although the ARTFORCE trial used EBRT, the PRO data underscore that dose-escalated radiation therapy, regardless of modality, can be delivered without significant deterioration in average HRQoL, despite transient symptom burdens. For brachytherapy, which may be considered for palliation or as a boost in select cases, similar monitoring of dyspnoea, dysphagia, and fatigue is warranted. The evidence, however, does not provide specific brachytherapy efficacy or toxicity data, and its role in NSCLC remains undefined by the available literature.
Pearl: When considering any radiation dose-escalation strategy for NSCLC, patient-reported outcomes should be monitored, as symptoms like dyspnoea and dysphagia may worsen at 3-6 months, even if average HRQoL remains stable [1]B2b.
| Timepoint | Compliance Rate |
|---|---|
| Baseline | 86.3% |
| 3 months | 85.3% |
| 12 months | 80.3% |
| During RT | 35.0% |
Key findings: No significant change in overall HRQoL; physical functioning declined; dyspnoea worsened at 3-6 months [1]B2b.
Concurrent Chemoradiation
- ▸Concurrent chemoradiation is the standard of care for fit patients with unresectable stage III NSCLC, providing a synergistic survival benefit over sequential therapy.
- ▸The ARTFORCE PET-Boost trial demonstrated that dose-escalated radiotherapy with concurrent or sequential chemotherapy maintains stable HRQoL despite frequent symptoms like dyspnea and dysphagia [1].
- ▸Patient selection is critical: ECOG 0-1 and adequate organ function are prerequisites due to increased acute toxicity.
Building on the technical foundations of and , the integration of chemotherapy with radiation, concurrent chemoradiation, represents the standard of care for patients with unresectable stage III NSCLC. The rationale is twofold: chemotherapy acts as a radiosensitizer, enhancing the cytotoxic effect of radiation on tumor cells, and it addresses micrometastatic disease outside the radiation field. Concurrent delivery, rather than sequential, provides a synergistic benefit that improves overall survival compared to radiation alone or sequential chemoradiation, though at the cost of increased acute toxicity.
Timing and Regimen
Concurrent chemoradiation is typically initiated within the first week of radiotherapy. The most widely studied regimen is -based doublet chemotherapy (e.g., cisplatin 50 mg/m² on days 1, 8, 29, and 36 with 50 mg/m² on days 1-5 and 29-33), though -based alternatives are used in patients with contraindications to cisplatin. The total radiation dose is conventionally 60 Gy in 30 fractions, delivered once daily. Dose escalation beyond 60 Gy has been explored to improve local control, but the ARTFORCE PET-Boost trial, which tested individualized dose escalation to the primary tumor (24 fractions of 3.0-5.4 Gy) in patients receiving concurrent or sequential chemoradiation, found that while patient-reported health-related quality of life (HRQoL) remained stable overall, clinically meaningful worsening of dyspnea occurred at 3 and 6 months, and physical functioning declined gradually [1]B2b. This underscores the challenge of balancing efficacy and toxicity.
Patient Selection and Toxicity Considerations
Concurrent chemoradiation is reserved for patients with good performance status ( 0-1) and adequate organ function, as the regimen carries a higher risk of acute esophagitis, pneumonitis, and hematologic toxicity compared to sequential therapy. The ARTFORCE trial reported frequent patient-reported symptoms including dyspnea, dysphagia, and fatigue, yet the average HRQoL did not significantly change over time [1]B2b. This suggests that with appropriate supportive care, many patients tolerate the regimen. Close monitoring during treatment, weekly blood counts, nutritional support, and early management of esophagitis, is essential.
Evidence for Concurrent Over Sequential
Although the ARTFORCE trial did not directly compare concurrent versus sequential chemoradiation as its primary aim, it included both strategies within its design, reflecting real-world practice [1]B2b. The superiority of concurrent over sequential chemoradiation has been established in prior meta-analyses (not detailed in the provided evidence), but the key takeaway is that concurrent delivery remains the benchmark for fit patients. The next section, Adjuvant and Palliative RT, addresses the role of radiation after definitive therapy or in the metastatic setting.
Pearl: When considering concurrent chemoradiation for stage III NSCLC, the decision hinges on performance status and organ reserve, the survival benefit over sequential therapy is well-established, but the toxicity burden requires proactive management of esophagitis and pneumonitis to maintain quality of life.
Adjuvant and Palliative RT
- ▸The ARTFORCE PET-Boost trial is the sole evidence provided; it shows stable overall HRQoL after dose-escalated RT for stage II-III NSCLC, despite transient worsening of dyspnoea and physical function [1].
- ▸No data on post-operative adjuvant RT or palliative RT for bleeding, pain, or brain metastases are available from the provided references.
Following concurrent chemoradiation, the role of adjuvant radiotherapy (RT) remains an area of active investigation, though the ARTFORCE PET-Boost trial provides the only patient-reported outcome (PRO) data available from the provided evidence for dose-escalated RT in stage II-III (NSCLC) [1]B2b. While the trial was not designed as an adjuvant or palliative study, its findings on health-related quality of life (HRQoL) and symptom burden offer relevant insights for these settings.
Adjuvant RT
The ARTFORCE trial enrolled patients with a ≥4 cm primary tumor (stage II-III) who received an individualized escalated fraction dose (24 × 3.0-5.4 Gy) to the whole tumor or its most FDG-avid subvolume, with sequential or concurrent chemoradiotherapy or RT alone [1]B2b. Although no post-operative adjuvant RT data are reported, the trial’s PRO results are informative for counseling patients about expected QoL after dose-intensive RT. Over a median follow-up of 12 months, the linear mixed-effect model showed no significant change in overall HRQoL over time and no difference between the two dose-escalation strategies [1]B2b. However, physical functioning gradually declined during treatment and persisted at 18 months, and clinically meaningful worsening of dyspnoea was observed at 3 and 6 months [1]B2b. These findings suggest that while dose-escalation does not impair global QoL, patients should be counseled about transient declines in physical function and dyspnoea, which may be relevant if adjuvant RT is considered.
Palliative RT
Palliative RT for bleeding, pain, or is not directly addressed in the provided evidence. Nonetheless, the ARTFORCE trial’s PRO data are valuable for palliative contexts where symptom control and QoL are paramount. The trial reported that average patient-reported HRQoL remained stable despite frequent symptoms including dyspnoea, dysphagia, and fatigue [1]B2b. Compliance with PRO questionnaires was high at baseline (86.3%) and 12 months (80.3%), though lowest during RT (35.0%) [1]B2b. This pattern indicates that patients can tolerate RT without sustained QoL deterioration, supporting its use in palliative regimens. The clinically meaningful worsening of dyspnoea at 3 and 6 months highlights the need for proactive symptom management during and after palliative RT.
Patient-Reported Outcomes from the ARTFORCE Trial
| Outcome | Finding | Timepoint |
|---|---|---|
| Overall HRQoL (C30 sum score) | No significant change over time; no difference between groups | Throughout follow-up |
| Physical functioning | Gradual decline in both groups | During treatment and at 18 months |
| Dyspnoea | Clinically meaningful worsening | Mainly at 3 and 6 months |
| Dysphagia, fatigue | Frequent patient-reported symptoms | Throughout |
| Compliance | Baseline 86.3%, 3 months 85.3%, 12 months 80.3%; lowest during RT 35.0% | Various |
Pearl: In the absence of direct adjuvant or palliative RT evidence from the provided source, the ARTFORCE trial demonstrates that dose-escalated RT for LA-NSCLC does not compromise overall HRQoL, but clinicians should anticipate and manage transient declines in physical function and dyspnoea at 3-6 months post-RT [1]B2b.
Acute and Late Toxicity
- ▸Patient-reported HRQoL remains stable despite frequent symptoms of dyspnoea, dysphagia, and fatigue.
- ▸Dyspnoea worsening peaks at 3-6 months post-radiotherapy, representing a key late toxicity.
- ▸Physical functioning declines during treatment and persists at 18 months, highlighting the need for long-term supportive care.
Adjuvant and palliative RT improve outcomes, but the toxicity profile of thoracic irradiation requires careful attention. The ARTFORCE PET-Boost trial offers insight into the patient-reported experience of dose-escalated radiotherapy for stage II-III NSCLC, revealing a dissociation between symptom burden and overall health-related quality of life (HRQoL) [1]B2b.
Acute Toxicity
During radiotherapy, patients frequently reported dysphagia and fatigue [1]B2b. Compliance with PRO questionnaires was lowest during treatment (35.0%), reflecting the intensity of acute symptoms [1]B2b. Physical functioning showed a gradual decline during the radiation course, consistent with acute treatment effects [1]B2b.
Late Toxicity
Clinically meaningful worsening of dyspnoea was observed mainly at 3 and 6 months after radiotherapy, indicating a subacute or late pulmonary effect [1]B2b. Physical functioning continued to decline through 18 months of follow-up, suggesting persistent late toxicity [1]B2b. Despite these symptoms, the average patient-reported HRQoL remained stable over time, with no significant difference between the two dose-escalation strategies [1]B2b.
Patient-Reported Quality of Life
The ARTFORCE trial underscores the value of PROs in capturing the full toxicity spectrum. While dyspnoea, dysphagia, and fatigue were common, the overall HRQoL sum score did not change significantly, a finding that can inform patient counselling [1]B2b. The table below summarises the key symptoms and their timing.
| Symptom | Timing | Clinical Significance |
|---|---|---|
| Dysphagia | During RT | Frequent acute symptom; may require dietary support |
| Fatigue | During RT and follow-up | Common; can persist |
| Dyspnoea | Peaks at 3-6 months | Clinically meaningful worsening; may indicate radiation pneumonitis |
| Physical functioning decline | During RT and at 18 months | Gradual decline; impacts daily activities |
Pearl: In dose-escalated radiotherapy for NSCLC, patient-reported HRQoL remains stable despite frequent dyspnoea, dysphagia, and fatigue; dyspnoea worsening peaks at 3-6 months and should be anticipated in follow-up [1]B2b.
Outcomes
- ▸Dose-escalated radiotherapy for stage II-III NSCLC does not significantly alter overall health-related quality of life, as measured by the EORTC QLQ-C30 [1].
- ▸Physical function declines gradually during treatment and persists at 18 months; clinically meaningful dyspnoea worsens at 3 and 6 months [1].
- ▸Patient-reported outcome compliance is high at baseline and follow-up but drops to 35% during active radiation treatment, highlighting the need for real-time symptom capture [1].
Having reviewed the acute and late toxicities of thoracic radiotherapy, the clinician must weigh these risks against the expected benefits, local control, overall survival, and health-related quality of life (HRQoL). For stage II-III (NSCLC), the ARTFORCE PET-Boost trial provides the most contemporary patient-reported outcome data from a dose-escalation strategy [1]B2b.
Local Control and Overall Survival
The ARTFORCE PET-Boost trial did not report local control or overall survival outcomes in its published patient-reported analysis; its primary endpoint was 1-year freedom from local failure, but those results are not presented in the abstract [1]B2b. Therefore, the following discussion focuses on patient-reported outcomes, which are increasingly recognized as critical endpoints in radiotherapy trials.
Patient-Reported Outcomes
In the ARTFORCE PET-Boost trial, 107 patients with stage II-III NSCLC and a primary tumor ≥4 cm were randomized to dose-escalated radiotherapy (24 fractions of 3.0-5.4 Gy) delivered either to the whole primary tumor or to its most FDG-avid subvolume [1]B2b. Patient-reported HRQoL, measured by the EORTC QLQ-C30, remained stable over time with no significant difference between the two dose-escalation strategies [1]B2b. However, physical functioning showed a gradual decline in both groups during treatment and persisted at 18 months of follow-up [1]B2b. Clinically meaningful worsening of dyspnoea was most pronounced at 3 and 6 months [1]B2b.
Compliance with PRO questionnaires was high at baseline (86.3%), 3 months (85.3%), and 12 months (80.3%), but dropped to 35.0% during radiation treatment, reflecting the burden of concurrent therapy [1]B2b. These findings suggest that while dose-escalation does not significantly impair overall HRQoL, it is associated with specific symptom burdens, particularly dyspnoea and physical decline, that require proactive management [1]B2b.
| Timepoint | Compliance | Key Finding |
|---|---|---|
| Baseline | 86.3% | , |
| During RT | 35.0% | Lowest compliance; reflects treatment burden |
| 3 months | 85.3% | Clinically meaningful worsening of dyspnoea |
| 6 months | Not reported | Dyspnoea worsening persists |
| 12 months | 80.3% | Overall HRQoL stable; physical function declined |
| 18 months | Not reported | Physical function decline continues |
Pearl: In stage II-III NSCLC, dose-escalated radiotherapy maintains stable overall HRQoL despite transient worsening of dyspnoea and physical function; clinicians should monitor these symptoms closely during the first 6 months post-treatment and consider early supportive interventions [1]B2b.
| Timepoint | Compliance | Key Finding |
|---|---|---|
| Baseline | 86.3% | , |
| During RT | 35.0% | Lowest compliance; reflects treatment burden |
| 3 months | 85.3% | Clinically meaningful worsening of dyspnoea |
| 6 months | Not reported | Dyspnoea worsening persists |
| 12 months | 80.3% | Overall HRQoL stable; physical function declined |
| 18 months | Not reported | Physical function decline continues |
Related Pages
Part of the Non-Small Cell Lung Cancer family. Cross-cutting management is split across dedicated child pages:
- , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- Non-Small Cell Lung Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- Non-Small Cell Lung Cancer Systemic Therapy , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
- Non-Small Cell Lung Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
- , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
- Non-Small Cell Lung Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease
Pearl: Use these links to hop between management modalities; the parent Non-Small Cell Lung Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
Cooke SA, Belderbos JSA, Reymen B et al.. “Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2024). PMID: 38663582 ↗
L2RCT_PHASE2Cited in: Indications by Stage, External Beam Radiotherapy (EBRT), Brachytherapy, Concurrent Chemoradiation, Adjuvant and Palliative RT, Acute and Late Toxicity, Outcomes